Name: Interface Between Regulation and Statistics in Drug Development (Chapman & Hall (en Inglés)
Price: 153370.00 CLP
Availability: InStock
Author: Demissie Alemayehu; Birol Emir; Michael Gaffney
ISBN: 9780367490485

portada Interface Between Regulation and Statistics in Drug Development (Chapman & Hall (en Inglés)

Formato

Libro Físico

Autor

Demissie Alemayehu; Birol Emir; Michael Gaffney

Año

2020

Idioma

Inglés

N° páginas

172

Encuadernación

Tapa Dura

ISBN13

9780367490485

N° edición

Categorías

Probabilidad y estadística

Interface Between Regulation and Statistics in Drug Development (Chapman & Hall (en Inglés)

Demissie Alemayehu; Birol Emir; Michael Gaffney (Autor) · · Tapa Dura

Libro Nuevo

$ 153.370

$ 213.020

Ahorras: $ 59.650

28% descuento

Envío normal

Origen: Estados Unidos (Costos de importación incluídos en el precio)

Se enviará desde nuestra bodega entre el Lunes 22 de Julio y el Martes 30 de Julio.

Lo recibirás en cualquier lugar de Chile entre 1 y 3 días hábiles luego del envío.

Reseña del libro "Interface Between Regulation and Statistics in Drug Development (Chapman & Hall (en Inglés)"

With the critical role of statistics in the design, conduct, analysis and reporting of clinical trials or observational studies intended for regulatory purposes, numerous guidelines have been issued by regulatory authorities around the world focusing on statistical issues related to drug development. However, the available literature on this important topic is sporadic, and often not readily accessible to drug developers or regulatory personnel. This book provides a systematic exposition of the interplay between the two disciplines, including emerging themes pertaining to the acceleration of the development of pharmaceutical medicines to serve patients with unmet needs. Features: Regulatory and statistical interactions throughout the drug development continuum The critical role of the statistician in relation to the changing regulatory and healthcare landscapes Statistical issues that commonly arise in the course of drug development and regulatory interactions Trending topics in drug development, with emphasis on current regulatory thinking and the associated challenges and opportunities The book is designed to be accessible to readers with an intermediate knowledge of statistics, and can be a useful resource to statisticians, medical researchers, and regulatory personnel in drug development, as well as graduate students in the health sciences. The authors' decades of experience in the pharmaceutical industry and academia, and extensive regulatory experience, comes through in the many examples throughout the book.